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Cilostazol Prevents Endothelin-Induced Smooth Muscle
Constriction and Proliferation
Yoshifumi Kawanabe1¤, Maki Takahashi1, Xingjian Jin1, Shakila Abdul-Majeed1, Andromeda M. Nauli2,
Youssef Sari1, Surya M. Nauli1*
1 Department of Pharmacology, The University of Toledo, Toledo, Ohio, United States of America, 2 Department of Health Sciences, East Tennessee State University,
Johnson City, Tennessee, United States of America

Abstract
Cilostazol is a phosphodiesterase inhibitor that has been shown to inhibit platelet activation. Endothelin is known to be the
most potent endogenous growth promoting and vasoactive peptide. In patients and animal models with stroke, the level of
circulating endothelin increases and complicates the recovery progress contributed by vascular constriction (an immediate
pathology) and vascular proliferation (a long-term pathology). However, the effects of cilostazol on endothelin have not
been explored. To demonstrate the dual-antagonizing effects of cilostazol on vasoconstriction and cell proliferation induced
by endothelin, we used primary culture of mouse vascular smooth muscle cells in vitro, mouse femoral artery ex vivo, and
intracranial basilar artery ex vivo. We show that the dual-inhibition effects of cilostazol are mediated by blocking endothelininduced extracellular calcium influx. Although cilostazol does not inhibit endothelin-induced intraorganellar calcium release,
blockade of extracellular calcium influx is sufficient to blunt endothelin-induced vasoconstriction. We also show that
cilostazol inhibits endothelin-induced cellular proliferation by blocking extracellular calcium influx. Inhibition of cAMPdependent protein kinase (PKA) can block anti-proliferation activity of cilostazol, confirming the downstream role of PKA in
cellular proliferation. To further demonstrate the selectivity of the dual-antagonizing effects of cilostazol, we used a different
phosphodiesterase inhibitor. Interestingly, sildenafil inhibits endothelin-induced vasoconstriction but not cellular
proliferation in smooth muscle cells. For the first time, we show selective dual-antagonizing effects of cilostazol on
endothelin. We propose that cilostazol is an excellent candidate to treat endothelin-associated diseases, such as stroke.
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models [10,11]. In smooth muscle cells, the immediate action of
endothelin is to trigger vasoconstriction (vasospasm), and its longterm effect is to promote cellular proliferation [12,13]. Thus, the
present study aims to examine the anti-vasoconstrictory and antiproliferatory effects of cilostazol in endothelin-induced models,
such as stroke.
We show for the first time that the dual actions of cilostazol can
prevent endothelin-induced vasoconstriction and cell proliferation
in mouse smooth muscle cells in vitro and ex vivo. Cilostazol prevents
endothelin-induced extracellular calcium influx but not intraorganellar calcium release. Furthermore, the anti-proliferation action
of cilostazol depends on the activation of cAMP-dependent protein
kinase (PKA) signaling pathway. Together, we propose that
cilostazol may have a therapeutic benefit to patients with stroke
where endothelin has been shown to complicate the post-stroke
recovery process [7–9].

Introduction
Cilostazol is a selective inhibitor of type-3 phosphodiesterase
(PDE), and it is currently used to treat peripheral vascular disease
of intermittent claudication [1,2]. Thus, the clinical benefit of
cilostazol is primarily set on its mechanism of action in preventing
activation or aggregation of platelets. In addition to its action on
platelets, it has been shown that cilostazol can promote
vasodilation [3]. Though the exact mechanism of this vasodilatory
effect is still debatable, it is known that cilostazol can reduce
cytosolic calcium concentration, which plays a key role in this
vasodilatation [4]. Furthermore, cilostzol has been shown to
decrease cellular proliferation [5,6]. Whether or not this action on
cellular proliferation depends on cytosolic calcium remains to be
determined.
Most importantly, the clinical benefits of cilostazol for its dualactions on vasodilation and anti-proliferation have not been
explored. We here propose that cilostazol has a unique property
for endothelin-associated diseases, such as proliferative vasospasm.
In particular, endothelin plays a major role after stroke and further
contributes significantly to complications in morbidity and
mortality. It has been known that after stroke, the level of
circulating endothelin increases in both patients [7–9] and animal
PLOS ONE | www.plosone.org

Materials and Methods
All animal procedures were approved by The University of
Toledo animal care and use committee. The use of primary cells and
other biohazard reagents was approved by the Institutional
Biosafety Committee of The University of Toledo. In our current
1

September 2012 | Volume 7 | Issue 9 | e44476

Cilostazol on Intracranial and Femoral Arteries

Table 1. Primer Sequences.

PDEs

Accession Numbers

PDE1

NM_001159582.1

PDE2

PDE3

NM_001143848.2

NM_018779.1

Primer Sequences

Positions

Forward: 59-TCCTGCCCTGCTTCAGCTGCTA-39

119

Reverse: 59-GGCGCTGCCACATCTTCTCGG-39

433

Forward: 59-GCCACTCACTGCTGCCTCCTG-39

991

Reverse: 59-CCTCATCTGTGAAGCTGGAAGTCGG-39

1315

Forward: 59-CGACCCTTCTCTGCCCCCGA-39

1398

Reverse: 59-GAAGGGGCTTCGTGCGGCTT-39

1730

Forward: 59-TACCGCAGTGAGCGAGCGAG-39

23

PDE4

NM_019798.5

Reverse: 59-AGGAGGTTTGGCCCAGTCCCTG-39

373

Forward: 59-TACAGCGGAGCGAGCACCCG-39

2052

PDE5

NM_153422.2

Reverse: 59-ATCGCAGAGAGGTCGCAGGC-39

2361

Forward: 59-GGAAGAGATCGTCGGCGTGGC-39

1288

Reverse: 59-CTCCGTGAGTGGCAGGTCGC-39

1651

Forward: 59-AGTGCCCCCTCTCTTCTGCCC-39

5

Reverse: 59-TGTTCCTGGCGGAGACTGATGCT-39

334

Forward: 59-TGTCCCACCACGGATTGCCCT-39

1545

Reverse: 59-CCCGCGTTGCACAGGAAGGA-39

1931

Forward: 59-GGTGGCAGAACCGTGGGTGG-39

1284

PDE6

PDE7

PDE8

PDE9

PDE10

PDE11

NM_146086.2

NM_008802.2

NM_008803.2

NM_008804.4

NM_011866.2

NM_001081033.1

Reverse: 59-AGTCTGTGCACACATTGAGATGTCC-39

1685

Forward: 59-CGCCGGTGGCCGAACTCTTT-39

253

Reverse: 59-GAGCAGGTGGTTGTCCCCGC-39

649

Forward 59-TGGTGGACGCTGACCGTTGC-39

741

Reverse: 59-TCGCCTGGGCCACACCGATA-39

1070

doi:10.1371/journal.pone.0044476.t001

studies, we used isolated primary smooth muscle cells from mouse
femoral arteries in vitro. We also utilized freshly isolated mouse
femoral and intracranial arteries ex vivo. The isolation of primary
cells is routinely performed in our laboratory [14,15], and primary
cultures of smooth muscle cells were confirmed with flow cytometry
and maintained at 39uC in Dulbecco’s Modification of Eagle’s
Medium (DMEM) containing 15% fetal bovine serum (FBS).

Cell Counting
For cell counting experiments, primary smooth muscle cells
were detached from femoral arteries and were grown on a 24-well
plate. A total of 6 wells per group (in the present and absent of
endothelin, cilostazol and/or a PKA inhibitor H-89) were used to
obtain measurements. Cell numbers were measured one well every
other day for about 2 weeks using hemocytometer. These
experiments were repeated four times for each group (N = 4).

Cytosolic Calcium Measurement
Isolated femoral (,200 mm in diameter) or basilar (,50 mm in
diameter) artery was cut into small pieces to form cylinder-like
shapes. Artery segments or isolated primary smooth muscle cells
were incubated with 5 mmol/L Fura2-AM for 30 minutes at 39uC
as previously described [14,15]. Basal calcium was equilibrated for
about 5 minutes in Dulbecco’s Phosphate-Buffered Saline (DPBS).
Paired fluorescence images of Fura2 at excitation wavelengths of
340 and 380 nm were recorded at every 4 seconds using Nikon
TE2000 microscope and analyzed using Metafluor software.

Immunofluorescence Study
Fluorescence study on isolated arteries has been previously
described [16,17]. Femoral artery was isolated and cleaned from
connective tissue. For basilar artery, the entire brain was used. The
basic principle for this labeling technique is to optimally induce
cell division followed by an optimal concentration and incubation
time of 5-bromo-deoxyuridine (BrdU). In our case, cell division
induced by 10 nM endothelin is optimally achieved in 24 hours ex
vivo. Cells undergoing division tend to uptake and incorporate
BrdU readily. A high concentration of BrdU or prolonged BrdU
incubation would result in a high background or a possibly false
positive result. Based on our titration experiments, the optimal
concentration and incubation time of BrdU are determined to be
60 mM and 15 minutes, respectively. Therefore, after incubation
with or without pharmacological agent(s) in DPBS for 24 hours,
60 mM of BrdU was added to the tissues for 15 minutes. The
tissues were then dipped in 4% paraformaldehyde for 2 days and
then embedded in 10% gelatin solution for sectioning. Once
solidified, the gelatin-containing tissues were submerged in 4%
paraformaldehyde for another 2 days. The artery segments or
brain tissues were sectioned at 50 mm using vibratome sectioning

Flow Cytometry Analysis
Primary smooth muscle cells were detached from femoral
arteries with trypsin-EDTA. After growing in culture for about 1
week, cells are permeabilized with ice-cold 100% ethanol. Total
RNA was digested with 0.5 mg/ml RNase A (Boehringer Mannheim,
Inc.) at 37uC for 30 minutes. The cells were then incubated with
20 mg/ml propidium iodide (PI; Sigma, Inc.) for 1 hour at room
temperature before analyzed with C6 Flow Cytometer (Accuri
Cytometers, Inc.).

PLOS ONE | www.plosone.org
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Figure 1. Cilostazol inhibits endothelin-induced extracellular calcium influx in a dose-dependent manner. a. Endothelin (ET) increases
intracellular free calcium in primary culture of mouse femoral smooth muscle cells in a biphasic manner. ET induces intraorganellar calcium release
(initial peak) and extracellular calcium influx (plateau phase). b. After the intracellular calcium increase is stabilized, dose-dependent effects of
cilostazol is examined by applying various concentrations of cilostazol to the cells. Percent changes in cytosolic calcium is presented on the right
panel (N = 4). c. Pretreatment with sub-optimal cilostazol concentration blocks endothelin-induced calcium influx but not calcium release. Effects of
endothelin-induced calcium influx and release are quantified in the presence or absence of cilostazol pretreatment (N = 5). d. 10 mM of thapsigargin
promotes release of intraorganellar calcium release. After the intracellular calcium increase is stabilized, sub-optimal concentration of cilostazol does
not show a substantial effect on calcium release (N = 4). e. Cilostazol has no significant role in 100 mM thapsigargin-induced calcium release (N = 5).
doi:10.1371/journal.pone.0044476.g001

and submerged in DPBS in the presence or absence of
pharmacological agent(s). After 30 minutes incubation at 39uC,
the brains were again photographed. The samples were then fixed
in formalin.
Two main observations were made before and after formalin
fixation. Before formalin fixation, we observed changes in the
vascular reflection line. This vascular line is visible due to
accumulation of red blood cells; i.e. vasodilated vasculatures
contain more red cells and thus are more visible than constricted
vasculatures. As such, vascular reflection line was used to indicate
vascular tone of tiny arterial branches. After formalin fixation,
samples were further processed for a standard procedure of H&E
staining with a thickness of 5 mm. The diameter of basilar artery

apparatus (Leica, Inc.). Sample sections were then treated with 2 N
HCl solution for 30 minutes and permeablized with 1% triton-X
solution for 5 minutes. Anti-BrdU antibody at 1:20 dilution for 1
hour followed with phalloidin staining at 1:80 dilution for 1 hour
were applied to the samples. The samples were then preserved
with Vectashield mounting media containing DAPI and analyzed
with Nikon Ti-U. Because endothelin also induces cell proliferation in other cell types, we quantified the BrdU staining in the
medial part of artery, which only contains smooth muscle cells.

Immunohistochemistry Study
To better examine vasoconstriction property of basilar arteries,
brains were isolated from adult mice, immediately photographed,

Figure 2. Cilostazol inhibits endothelin-induced cytosolic calcium increase and vasoconstiction in mouse femoral arteries. a.
Cytosolic calcium (pseudocolor) and inner diameter (arrows) of femoral arteries are studied ex vivo. Segment of artery is imaged and recorded before
and after endothelin (ET) treatment in the presence or absence of cilostazol and/or H-89. Artery segment is pseudocolored to denote changes in
cytosolic free calcium level from low to high (hi) as indicated in the color bar. b. Cilostazol significantly decreases endothelin-induced cytosolic
calcium increase. c. Changes in diameter denoting vascular constriction are expressed in percentage relative to baseline diameter prior to endothelin
treatment. N = 5.
doi:10.1371/journal.pone.0044476.g002
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Figure 3. Cilostazol inhibits endothelin-induced calcium increase and vasoconstriction in mouse intracranial arteries. a. Cytosolic
calcium of basilar arteries are studied ex vivo. Segment of artery is imaged and recorded before and after endothelin (ET) treatment in the presence or
absence of cilostazol. Artery segment is pseudocolored to denote changes in cytosolic free calcium level from low to high (hi) as indicated in the color
bar. b. Micrographs show the pons region of the whole brain before and after endothelin treatment in the presence or absence of cilostazol and/or
H-89. The vascular reflection line denoting vascular tone (constriction) of intracranial arteries is adequately visible. Arrowheads point at the anterior
inferior cerebellar arteries or basilar arteries to compare vascular tone before and after treatment. Sagittal sections of mouse brain are obtained at the
pons, near the interpeduncular fossa boundary. A standard H&E staining is shown in the far right. Red box indicates the area of interest, where basilar
artery is located. Arrows denote basilar artery constriction. Bar = 50 mm c. Cilostazol significantly decreases endothelin-induced cytosolic calcium
increase. Administration of H-89 blocks the effect of cilostazol d. Changes in diameter denoting vascular constriction are expressed in percentage
relative to baseline diameter prior to endothelin treatment. N = 5.
doi:10.1371/journal.pone.0044476.g003

was more accurately measured with this type of cross-section
preparation.

Pharmacological Treatment
Cultured cells, artery segments or cerebral vasculatures were
stimulated with 10 nM endothelin, as previously described
[20,21]. In some groups, various concentrations of cilostazol were
added before or after endothelin stimulation. In other groups,
cultured cells, artery segments or cerebral vasculatures were
incubated in DPBS for 24 hours at 39uC with or without
endothelin (10 or 100 nM) in the presence or absence of cilostazol
(30 mM) and/or H-89 (10 mM). In some cases, sildenafil (30 mM)
was used in the presence or absence of endothelin. In all cases,
pharmacological agents were diluted to the concentrations so that
the exact same volume of solution was added to the samples, in an
effort to maintain identical volume. Cell and tissue culture
reagents were purchased from Cellgro, Inc. All other reagents,

Reverse-transcription Polymerase Chain Reaction (RTPCR)
To examine distribution of PDE subtypes in smooth muscle
cells, we performed semi quantitative RT-PCR studies. The
primer sequences were designed based on the accession numbers
obtained from the National Center for Biotechnology Information
(Table 1). The experimental details follows previously published
protocols [18,19].

Figure 4. Cilostazol inhibits endothelin-induced cell proliferation in vascular smooth muscle cells. a. Endothelin (ET) at 10 and 100 nM
increases cell proliferation in primary culture of smooth muscle cells as indicated by flow cytometry study. Cell proliferation is studied with nuclear
marker, propodium iodide (PI). b. Cilostazol significantly decreases endothelin-induced cellular division. Effect of cilostazol can be blocked by H-89
(N = 3). c. Cell counting experiments were performed in the present and absent of ET, cilostazol and/or H-89. Cilostazol significantly decreases
endothelin-induced cell growth. H-89 attenuates the effect of cilostazol in endothelin-induced cell growth (N = 4).
doi:10.1371/journal.pone.0044476.g004
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Figure 5. Cilostazol inhibits endothelin-induced cell proliferation in mouse femoral arteries. Effects of endothelin (ET) in the presence or
absence of cilostazol and PKA inhibitor (H-89) on cell proliferation are studied with immunolabeling in femoral arteries ex vivo. Segment of artery is
imaged and recorded for phase contrast to indicate the morphology of the artery, dapi to visualize cell nucleus, a-actin to outline contractile smooth
muscle cells and BrdU to determine cellular proliferation property of the vascular cells. Endothelin increases cell proliferation as indicated by BrdU
staining and cell growth into the lumen of the artery. Cilostazol blocks cell proliferation induced by endothelin, and H-89 inhibits efficacy of cilostazol.
White box denotes a larger magnification. Asterisk indicates significant difference in fluorescence intensity per area within the smooth muscle cells,
compared to control groups. N = 4.
doi:10.1371/journal.pone.0044476.g005

including endothelin and cilostazol, were purchased from Sigma
Aldrich, Inc, except for DAPI (Vector Laboratories, Inc.) and phalloidin
and anti-Brdu antibodies (Invitorgen, Inc.).

Data Analysis
Experiments were repeated on different sets of cell populations
at least three times. When primary cells were used, cells were also

Figure 6. Cilostazol inhibits endothelin-induced cell proliferation in mouse basilar arteries. Effects of endothelin (ET) in the presence or
absence of cilostazol and PKA inhibitor (H-89) on cell proliferation are studied with immunolabeling in basilar arteries ex vivo. Segment of artery is
imaged and recorded for phase contrast to indicate the morphology of the artery, dapi to visualize cell nucleus, a-actin to outline contractile smooth
muscle cells and BrdU to determine cellular proliferation property of the vascular cells. Endothelin increases cell proliferation as indicated by BrdU
staining. Cilostazol blocks cell proliferation induced by endothelin, and H-89 inhibits efficacy of cilostazol. White box denotes a larger magnification.
Asterisk indicates significant difference in fluorescence intensity per area within the smooth muscle cells, compared to control groups. N = 3.
doi:10.1371/journal.pone.0044476.g006
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Figure 7. Sildenafil inhibits endothelin-induced vasoconstriction but not cellular proliferation in smooth muscle cells. a. To identify
distribution of phosphodiesterase (PDE) subtypes, semi-quantitative RT-PCR was performed. Mouse brain homogenate was used as an internal
control. b. To examine the roles of PDE5 in smooth muscle cells, we applied sildenafil on basilar arteries. Sildenafil significantly decreases endothelininduced cytosolic calcium increase and vascular constriction. c. Unlike cilostazol, sildenafil does not have any effect on endothelin-induced cellular
proliferation of smooth muscle cells. N = 3.
doi:10.1371/journal.pone.0044476.g007

calcium, the transient peak was unaffected, but the sustained
increase was abolished (data not shown), indicating that a
sustained increase in intracellular calcium is a result from
extracellular calcium influx. On the other hand, the transient
increase is a result of mobilization of calcium from the
intraorganellar calcium store.
The sustained increase in cytosolic calcium by endothelin was
suppressed by cilostazol in a concentration-dependent manner
with IC50 values of around 3 mM. In endothelin-induced cytosolic
calcium increase, 3 mM of cilostazol is the suboptimal concentration to return cytosolic calcium to the baseline level (Figure 1b).
We therefore used this concentration throughout our experiments
with cilostazol. To differentiate effects of cilostazol on calcium
influx versus calcium release, we pre-incubated the cells with
cilostazol (Figure 1c). In the presence of cilostazol, endothelin has
no effect in maintaining a steady increase in cytosolic calcium,
indicating that cilostazol selectively blocks calcium influx. To
confirm this finding, we examined the effect of cilostazol on 10 or
100 mM thapsigargin-induced calcium release (Figure 1d or 1e).
Consistent with our previous results, cilostazol has minimal or
insignificant effect on intraorganellar calcium release.

isolated from at least three different animals (N$3 for each group).
A minimum of six coverslips for each experiment was used for
immunostaining analysis, and a minimum of five sections was cut
for immunohistochemistry study. All quantifiable data were
reported as mean 6 SEM. Comparison between two groups was
carried out using Student t-test. Data comparisons for more than
two groups were done using ANOVA test, followed by Tukey
posttest analysis. The difference between groups was considered
statistically significant at p,0.05. All statistical analysis was done
with GraphPad Prism, version 5.0.

Results
Cilostazol Specifically Blocks Extracellular Calcium Influx
Although cilostazol has been reported to alter cytosolic calcium,
it is still not clear if effects of cilostazol on repressing cytosolic
calcium are associated with extracellular calcium influx, intraorganellar calcium release, or by both mechanisms. In this study, we
first identify the concentration of cilostazol required for an optimal
response in vascular smooth muscle cells. We used the most potent
vasoconstrictor (endothelin) and primary culture of smooth muscle
cells isolated from the mouse femoral artery.
Endothelin at 10 nM induced a biphasic increase in intracellular free calcium, consisting of a transient peak and a subsequent
sustained increase (Figure 1a). After removal of extracellular

PLOS ONE | www.plosone.org
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(Figure 3a). Submaximal concentration of 30 mM cilostazol
inhibits endothelin-induced cytosolic calcium increase.
To examine effects of cilostazol on the brain vasculature,
intracranial arteries were compared before and after cilostazol
treatment in the presence and absence of endothelin and/or H-89
(Figure 3b). Because of the minute sizes of the cerebral arteries in
the mouse, we used vascular reflection line as a measurement of
vascular tone. Of note is that endothelin has a greater
vasoconstriction effect on smaller rather than larger arterial
branches. Thus, the effects of cilostazol on endothelin-induced
constriction are more noticeable in anterior inferior cerebellar
arteries and basilar arteries. To further examine the anatomy of
basilar arteries more closely, we analyzed sagittal sections at the
area of pons-interpeduncular fossa boundary. Consistent with our
femoral studies, endothelin can cause intracellular calcium
increase (Figure 3c) and vasoconstriction (Figure 3d). Furthermore, H-89 can block the inhibitory effects of cilostazol.

Cilostazol Inhibits Cell Proliferation in Vascular Smooth
Muscle Cells through PKA
While the short-term effect of endothelin is to induce
vasoconstriction, the long-term effect of endothelin is known to
promote mitogenic response (cellular proliferation) [12,13]. To
examine if cilostazol can also inhibit the long-term effect of
endothelin, we analyzed endothelin-induced cell proliferation in
isolated smooth muscle cells in the presence and absence of
cilostazol and/or H-89 (Figure 4a). Endothelin induces cell
proliferation in a dose-dependent manner (10 vs. 100 nM;
Figure 4b). The effect of endothelin on cell proliferation is
inhibited by cilostazol, as indicated by nuclear marker propidium
iodide. In colorimetric cell proliferation assay, cilostazol also
inhibits cell proliferation induced by 10 nM endothelin in a
concentration-dependent manner with IC50 values of around
3 mM (data not shown). Our in vitro studies were further confirmed
by cell counting experiments (Figure 4c). Endothelin induces
increase in cell numbers, which can be repressed by cilostazol.
Furthermore, the effect of cilostazol on cell growth can be blocked
with H-89.

Figure 8. Working model depicts the roles of cilostazol on
extracellular calcium influx in smooth muscle cells. Trimeric Gproteins (Gs or Gq) can activate downstream effectors, such as
adenylate cyclase (AC) or phospholipase C (PLC). Endothelin receptor
is coupled with Gq and can activate PLC. PLC hydrolyzes PIP2 to IP3
(induces intraorganellar calcium release) and DAG (promotes extracellular calcium influx). Cilostazol inhibits phosphodiesterase 3 (PDE3),
thereby preventing degradation of cAMP to AMP. PKA (cAMP
dependent protein kinase) can inhibit calcium influx in smooth muscle
cells. Thus, cilostazol inhibits endothelin-induced smooth muscle
contraction and cell proliferation by inhibiting calcium influx through
PKA activation.
doi:10.1371/journal.pone.0044476.g008

Cilostazol Inhibits Intracelluar Calcium Increase and
Vasoconstriction in Mouse Femoral Arteries through PKA
To further investigate the inhibitory effect of cilostazol on
extracellular calcium influx and vasoconstriction, we challenged
femoral arteries with endothelin ex vivo (Figure 2a). Endothelin
not only increases cytosolic calcium but also induces vasoconstriction of blood vessel. Submaximal concentration of cilostazol
(30 mM) inhibits cytosolic calcium increase and vasoconstriction
induced by 10 nM endothelin. These data suggest that inhibiting
calcium influx by cilostazol is sufficient to prevent endothelininduced vasospasm.
Because cilostazol inhibits phosphodiesterase-3 (PDE3), increases cAMP level and thereby activates cAMP-dependent protein
kinase (PKA), we used PKA inhibitor (H-89) to identify a potential
molecular mechanism in the inhibiting effects of cilostazol in our
experimental model. Our data show that H-89 could block
efficacy of cilostazol-induced calcium influx (Figure 2b) and
vasoconstriction (Figure 2c).

Cilostazol Inhibits Cell Proliferation in Femoral and Basilar
Arteries through PKA
To verify the potential inhibitory mechanism on cell proliferation from our in vitro data, we next investigated the effects on
cilostazol ex vivo using isolated mouse femoral and basilar arteries.
We used BrdU as a marker of cell proliferation. In both femoral
(Figure 5) and basilar (Figure 6) arteries, endothelin induces a
gross cell proliferation as indicated by both dapi and BrdU
florescence images. The effect of endothelin in cell growth is
inhibited with cilostazol treatment. As expected, inhibiting PKA
blocks efficacy of cilostazol on cell growth. Of note is that
simultaneous administration of endothelin and H-89 also causes
intima thickening, as a result from the peripheral cell proliferation.
Our studies demonstrate that cilostazol can inhibit cell growth
induced by endothelin in both peripheral and intracranial arteries.

Cilostazol Inhibits Intracelluar Calcium Increase and
Vasoconstriction in Intracranial Arteries through PKA

Sildenafil Inhibits Endothelin-induced Vasoconstriction
but not Cellular Proliferation in Smooth Muscle Cells

Because the most prominent pathological relevance of endothelin-induced cellular proliferation and vasospasms occurs during
stroke, we extended our studies using brain tissues. Due to
technical challenges with intracranial arteries, our calcium and
constriction studies were performed separately. As expected,
endothelin increases cytosolic calcium in basilar arteries
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To examine the specificity of cilostazol effects on its vasoconstriction and proliferation inhibitions, we screened the distribution
of PDE subtypes in smooth muscle cells. As expected, PDE3 is
clearly present in the smooth muscle cells (Figure 7a). Because
other PDE subtypes are also detected, we chose to identify effects
of PDE5 inhibition. Sildenafil, a specific PDE5 inhibitor, blocks
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endothelin-induced cytosolic calcium increase and basilar artery
contraction (Figure 7b). Unlike cilostazol, however, sildenafil has
no effect on cellular proliferation of smooth muscle cells
(Figure 7c). All in all, our results indicate that cilostazol can
specifically inhibit vasoconstriction and cell growth induced by
endothelin in vascular smooth muscle cells.

similar effect on arterial segments challenged with endothelin first
(not shown). Regardless, our studies on cultured cells in vitro and
isolated tissues ex vivo show that cilostazol has an inhibitory effect
on calcium influx and vasoconstriction.
We and others have also shown that endothelin can induce
cellular proliferation in vascular smooth muscle cells [20,26].
Furthermore, it has been shown that calcium influx can promote
cellular proliferation [27]. To examine effect of cilostazol on
proliferation by endothelin-induced calcium influx, we performed
a standard cellular proliferation assay. Consistent with previous
studies [20,26], endothelin significantly increases baseline level of
cellular proliferation. Pre-treatment with cilostazol is sufficient to
block cellular proliferation induced by endothelin in primary
cultured smooth muscle cells. To confirm these in vitro results, we
performed ex vivo studies on mouse femoral and basilar arteries. As
indicated by nuclear marker (dapi), endothelin increases cell
numbers, where cells have grown toward the lumen of the artery
segment. As indicated by proliferative marker (BrdU), endothelin
increases cellular proliferation, especially on the newly dividing
cells around the lumen of the artery.
It has been known for a while that endothelin plays an
important role in hypertension and stroke. However, the impact of
endothelin in cerebral microcirculation is not known. In particular, a high level of circulating endothelin is detected in patients
with stroke [7–9]. It has been hypothesized that endothelin plays a
major role in vascular injury and contributes to seizures, coma and
death in these patients. We thus examine the effects of endothelin
and cilostazol in the intracranial arteries. Consistent with our cell
culture in vitro and femoral artery ex vivo studies, cilostazol also
inhibits endothelin-induced vasoconstriction in basilar artery ex
vivo. The vasoconstriction effect of endothelin is especially more
apparent in the anterior inferior cerebellar arteries. Endothelininduced vasoconstriction is further confirmed in basilar arteries
and other intracranial arteries surrounding Circle of Willis (not
shown). Most important is that cilostazol can sufficiently inhibit
the effect of endothelin.
Because inhibition of PDE3 has been shown to increase PKA
activity, we used PKA inhibitor (H-89) to examine the molecular
mechanism of cilostazol. Our data suggest that PKA inhibition can
abolish the inhibitory effect of cilostazol on endothelin. It is
generally known that PKA can block both calcium influx [28,29]
and cellular proliferation [30]. Furthermore, cilostazol has been
shown to increase PKA activity through an increase in baseline
cAMP level [6,31]. We therefore propose that inhibitory effects of
cilostazol on endothelin depend on both calcium influx and/or
PKA activity.
Supporting our working model (Figure 7), we used a specific
PDE5 inhibitor sildenafil in our experimental system. Although
sildenafil blocks endothelin-induced cytosolic calcium increase and
basilar artery contraction, it has no effect on cellular proliferation
of smooth muscle cells. PDE5 has been shown to promote cGMP
degradation. This is consistent with our previous work demonstrating that cGMP decreases cytosolic calcium and induces
vasodilation [32–34]. In summary, our studies provide the first
evidence on the specific-dual inhibitory effects of cilostazol on
endothelin-induced vasoconstriction and cellular proliferation.
Our studies also offer a possible mechanism by which cilostazol
has been tried in clinical study associated with stroke [1].
Together, we propose that cilostazol has a therapeutic benefit to
post-stroke patients where endothelin has been shown to
complicate the progression of the recovery.

Discussion
In the present study, we show for the first time that cilostazol
has a unique property to block activity of endothelin-induced
vasospasm and cellular proliferation (Figure 8). Our in vitro and ex
vivo studies further demonstrate that cilostazol blocks endothelin
function by inhibiting endothelin-induced extracellular calcium
influx. Endothelin promotes cellular proliferation phenotype in
vascular smooth muscle cells and mouse femoral and basilar
arteries. Furthermore, the action of cilostazol on blocking this
cellular proliferation depends on the activity of PKA. Our studies
suggest a possible mechanism of cilostazol in treating patients
associated with endothelin overload, such as hyperproliferation
and vasospasm.
Cilostazol is a phosphodiesterase inhibitor that prevents platelet
aggregation by increasing cAMP level and thereby activating
PKA. Although cilostazol is FDA-approved agent for treating
intermittent claudication, it has been suggested that cilostazol can
treat other cardiovascular diseases. Based on its vasodilation
activity, for example, cilostazol has been proposed to be a possible
regimen for patients with congestive heart failure, ischemic stroke,
post-stent thrombosis, and other atherothrombotic vascular
diseases [1,2]. Based on its anti-proliferation activity, cilostazol
has also been suggested to reduce cardiac hypertrophy and
attenuate the overall cardiac remodeling [22]. In the present study,
we examined the effects of cilostazol in the presence of endothelin,
which is known to be a potent vasoconstrictor and cell growth
promoter.
Endothelin is known to be the most potent endogenous growth
promoting and vasoactive peptide. It is therefore not surprising
that over production of endothelin has been associated with many
types of cancer and cardiovascular disorders. Accordingly,
endothelin receptor blockers (such as atrasentan and bosentan)
have been clinically tested in ovarian cancer and pulmonary
hypertension [13,23,24]. More importantly, one of the endothelin
blockers (clazosentan) is currently under phase-3 clinical trial to
treat patients with aneurysmal subarachnoid hemorrhage [25].
The consensus is that endothelin plays a major role in acute
vascular injury. In particular, endothelin contributes to major
complications resulting in morbidity and mortality of patients with
stroke [7–9].
We and others have previously shown that endothelin can
induce both extracellular calcium influx and intraorganellar
calcium release in smooth muscle cells [12,13]. In the present
study, we show that while cilostazol has a minor effect on
endothelin-induced calcium release, it has a significant inhibitory
effect on calcium influx in a dose-dependent manner. We further
show that pre-treatment of cilostazol also has equipotent efficacy
on calcium influx but not on calcium release. To further confirm
the mechanism of action of cilostazol, we utilized thapsigargin to
induce intracellular calcium release. As expected, we consistently
observe that cilostazol has a minor role on calcium release,
induced by either endothelin or thapsigargin. To validate our in
vitro results, we performed ex vivo studies on mouse femoral arteries.
As expected, endothelin causes an increase in cytosolic calcium
and vasoconstriction. These effects are blocked in arteries after 30
minutes pre-treatment with cilostazol. Cilostazol also shows a
PLOS ONE | www.plosone.org
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